Friday, June 23, 2017 9:27:33 PM
DCTH must retain at least $1.00 in stock value for 10 days prior to August 14 or be De-listed from the NASDAQ. Now in order to maintain the $1.00 the stock would have to gain a price in excess of the $1.00. The company has the rest of this month and all of July + 4 days of August to get the price up. I believe they have something up their sleeve for this to happen. One of the reasons I say that is the fact that none of the executives have sold any shares.
That is one possibility, another is they have a sale pending and the buyer would have to pay in excess of $1.00 per share to maintain the company position on the NASDAQ
All this banter between the shorts and the longs is a waste of efforts because the outcome is way beyond their control. The outcome of the companies future is being controlled by insiders and they are not divulging any information at this time.
When the Fish speaks, people listen!
This is only my opinion.
Recent DCTH News
- Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT • PR Newswire (US) • 05/06/2024 01:00:00 PM
- Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/03/2024 09:15:00 PM
- Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/04/2024 12:35:00 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • PR Newswire (US) • 03/26/2024 11:30:00 AM
- Delcath Systems Closes $7 Million Private Placement • PR Newswire (US) • 03/20/2024 12:15:00 PM
- Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call • PR Newswire (US) • 03/19/2024 01:00:00 PM
- Delcath Systems Appoints Martha S. Rook as Chief Operating Officer • PR Newswire (US) • 03/18/2024 09:20:00 PM
- Delcath Systems Announces $7 Million Private Placement • PR Newswire (US) • 03/15/2024 12:20:00 PM
- Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 03/08/2024 10:00:00 PM
- Delcath Systems to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/08/2024 02:00:00 PM
- Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System) • PR Newswire (US) • 02/22/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:26:39 PM
- Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 02/16/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:46:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:46:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:44:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:44:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:43:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:03:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:08:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:00:11 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:26:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 02:37:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:03:03 PM
- Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024 • PR Newswire (US) • 01/31/2024 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM